(AChR)
| Name
| Method
| Reference Range
| Units
|
| AChR Binding Autoantibodies |
RIA |
< .25 |
nmol/L |
| No
| Type
| Volume
| Temperature
| Container Type
| Instructions
|
| 1 |
Serum |
1 (0.2) mL |
Refrigerated - 14 Day(s)/Frozen - 2 Month(s) |
Aliquot |
|
| 2 |
Plasma Heparinized |
1 (0.2) mL |
Refrigerated - 14 Day(s)/Frozen - 2 Month(s) |
Green |
|
| 3 |
Plasma EDTA |
1 (0.2) mL |
Refrigerated - 14 Day(s)/Frozen - 2 Month(s) |
Lavender |
|
| Setup Schedule |
Tuesday, Friday |
| Reported |
2 days |
| CPT Code
|
83519 |
| Notes |
Prices might not include a handling fee. |
| Clinical
Utilities |
Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.
|
|
